Cedars-Sinai Medical Center

medical staff pulse newsletter

Text size: A A A
A BI-WEEKLY PUBLICATION FROM THE CEDARS-SINAI CHIEF OF STAFF November 20, 2015 | Archived Issues

P & T Approvals, FDA Statement About Plavix

Pharmacy Focus

See highlights of the October meeting of the Pharmacy and Therapeutics Committee. Also, the U.S. Food and Drug Administration says that long-term use of Plavix does not change the risk of death for patients with heart disease.

» Read more


Meetings and Events


Grand Rounds

Click here to view upcoming grand rounds.


Upcoming CME Conferences

Click below to view a complete list of all scheduled Continuing Medical Education conferences.

CME Newsletter - November 2015 (PDF)  


Milestones

Viorica Ionut, MD, PhD, Ali Kashani, MD, and Arnold Klein, MD, have died.

» Read more

Share Your News

Won any awards or had an article accepted for publication? Share your news about professional achievements and other items of interest.

Click here to share your news

P & T Approvals, FDA Statement About Plavix

Pharmacy Focus

Highlights of the October meeting of the Pharmacy and Therapeutics Committee are summarized in the PDF link below. Also, the U.S. Food and Drug Administration says that long-term use of Plavix does not change the risk of death for patients with heart disease.

P&T Approvals - October 2015 (PDF)  

FDA: Long-Term Use of Plavix Does Not Change Risk of Death

A review by the U.S. Food and Drug Administration has determined that long-term use of the blood-thinning drug Plavix (clopidogrel) does not increase or decrease overall risk of death in patients with, or at risk for, heart disease. FDA evaluation of several clinical trials also does not suggest that clopidogrel increases the risk of cancer or death from cancer.

The FDA analysis indicates that long-term (12 months or longer) dual antiplatelet therapy with clopidogrel and aspirin does not appear to change the overall risk of death when compared to short-term (six months or less) clopidogrel and aspirin, or aspirin alone. Also, there was no apparent increase in the risk of cancer-related deaths or cancer-related adverse events with long-term treatment.

For more information, click here.